Chair
Cancer Biology
Cleveland Clinic Lerner Research Institute
United States of America
The Yi Laboratory has been working on tumor immunology and immunotherapy in multiple myeloma (MM) for 20 years. We were first to demonstrate the existence of idiotype-specific T cells in patients with MM and related disorders and that idiotype-specific cytotoxic T cells could lyse autologous primary myeloma cells.
My group is generating novel monoclonal antibodies (mAbs) to treat patients with MM and other cancers. We discovered that mAbs specific to human b2-microglobulin (b2M) induce programmed death of MM and other hematological tumor cells. These mAbs were also active and therapeutic in vivo in xenograft mouse models. Our goal is to develop these and other mAbs as therapeutic agents to treat patients with MM and other malignancies.